
Health Care professionals
For health care professionals
Seattle Cancer Care Alliance (SCCA) is a nationally recognized treatment center that provides advanced therapies and clinical trials for cancers and other blood disorders. SCCA unites the doctors and technology from Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Children's and provides a variety of resources for community doctors and other healthcare professionals.
Podcasts
- Seeking a breakthrough in DLBCL combination therapies with Dr. Ryan Lynch
- Understanding treatment options for standard- and high-risk CLL with Dr. Mazyar Shadman
- New data on risks and treatment for patients with cancer and COVID-19
- SCCA Offers Appleby Procedure
- SCCA is Committed to Bring World-Class Cancer Treatment to Patients in Their Own Communities
Publications
- American Society of Hematology Abstract: Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial
- American Society of Hematology Abstract: Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- American Society of Hematology Abstract: Existing Agents, Novel Agents, or Transplantation for High Risk MDS
Clinical trials
- MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma
- Investigator: Andrew Coveler, MD
- In our ongoing effort to support pancreatic cancer patients, SCCA is offering a groundbreaking trial that combines immunotherapy and chemotherapy. Recent research is finding that when new immunotherapy drugs are given with chemotherapy (anti-cancer) drugs that the cancer growth can slow down or stop for longer periods of time and keep your cancer from getting bigger.
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
- Investigator: Andrew J. Cowan, MD
- Phase I Study of Adoptive Immunotherapy with CD8+ and CD4+ Memory T cells Transduced to Express an HA-1-specific T cell Receptor (TCR) for Children and Adults with Recurrent Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
- Investigator: Elizabeth F. Krakow, MD, MSc
- Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
- Investigator: Masumi Ueda, MD
- Investigator: Masumi Ueda, MD
Physician talks
- Sarcoma Journal Club
- Drs. Matthew J. Thompson and Jesse L. Roberts
- February 17, 2021 at 7:00 pm PST
New providers

Lauren DeStefano, MD
Physician
Breast cancer

Cristina M. Ghiuzeli, MD
Physician
Leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)

Ragisha Gopalakrishnan, MD
Physician
Medical oncology, hematology, breast and thoracic cancers

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO
Physician
Gastrointestinal surgical oncology, hyperthermic intraperitoneal chemotherapy, soft tissue tumors, neuroendocrine tumors, melanoma

Jesse L. Roberts, MD
Physician
Orthopedic oncology, bone and soft tissue sarcomas in pediatric and adult populations

Anoop Patel, MD
Physician
Neurological surgery, brain and spinal cord tumors